Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Oxaliplatin 288Capecitabine 218Fluorouracil 213Irinotecan 146Leucovorin 140Gemcitabine 124S 1 (combination) 110apatinib 109Cisplatin 102Bevacizumab 99Drug Therapy 98Radiotherapy 97Paclitaxel 97camrelizumab 89sintilimab 79Cetuximab 75lenvatinib 62Neoadjuvant Therapy 61tislelizumab 55Surgical Procedures, Operative 54Sorafenib 53Folfox protocol 53toripalimab 52Docetaxel 52130-nm albumin-bound paclitaxel 47Laparoscopy 41HMPL-013 40XELOX 39Radiosurgery 36Albumin-Bound Paclitaxel 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Canagliflozin × Gastrointestinal × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡